Disease · MONDO_0020311
chronic myelomonocytic leukemia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. chronic myelomonocytic leukemia. Diseases, record MONDO_0020311. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020311
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- CMML, chronic myelomonocytic leukaemia (CMML), chronic myelomonocytic leukemia (CMML)
- Open Targets
- Highest stage of its drugs
- Approval, for 2 of its 118 drugs, from DailyMed and EMA Human Drugs
- Open Targets
Drugs118
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AZACITIDINE | CHEMBL1489 | Small molecule | Approval | DailyMed and EMA Human Drugs | 71 | 60 | 58 | Drugs and targets |
| DECITABINE | CHEMBL1201129 | Small molecule | Approval | DailyMed | 28 | 21 | 21 | Drugs and targets |
| CEDAZURIDINE | CHEMBL3237547 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 8 | 8 | Drugs and targets |
| PEVONEDISTAT | CHEMBL1231160 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| GLASDEGIB | CHEMBL2043437 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| GUADECITABINE | CHEMBL3544916 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| HYDROXYUREA | CHEMBL467 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LONAFARNIB | CHEMBL298734 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SABATOLIMAB | CHEMBL4594575 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TIMDARPACEPT | CHEMBL5314779 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 118
See all 118 drugsTargets169
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | 7 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 2 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 5 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| RRM1 | Ribonucleoside-diphosphate reductase RR1 | 5 | Ribonucleoside-diphosphate reductase RR1 inhibitor; Ribonucleotide reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/6240 | Drugs and targets |
| RRM2B | Ribonucleoside-diphosphate reductase RR1 | 5 | Ribonucleoside-diphosphate reductase RR1 inhibitor; Ribonucleotide reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/50484 | Drugs and targets |
| JAK2 | Tyrosine-protein kinase JAK2 | 4 | Tyrosine-protein kinase JAK2 inhibitor | Phase 2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| POLA1 | DNA polymerase (alpha/delta/epsilon) | 4 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/5422 | Drugs and targets |
| POLA2 | DNA polymerase (alpha/delta/epsilon) | 4 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/23649 | Drugs and targets |
| POLD1 | DNA polymerase (alpha/delta/epsilon) | 4 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/5424 | Drugs and targets |
| POLD2 | DNA polymerase (alpha/delta/epsilon) | 4 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/5425 | Drugs and targets |
| POLD3 | DNA polymerase (alpha/delta/epsilon) | 4 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/10714 | Drugs and targets |
1 to 10 of 169
See all 169 targetsTrials149
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04266301 | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | Phase 3 | 530 | 2025-12-12 | Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | AZACITIDINE, SABATOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03268954 | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) | Phase 3 | 454 | 2022-09-22 | Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute | AZACITIDINE, PEVONEDISTAT | Its record names the disease | ClinicalTrials.gov |
| NCT02907359 | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | Phase 3 | 417 | 2023-05-18 | Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | GUADECITABINE | Its record names the disease | ClinicalTrials.gov |
| NCT01522976 | Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | Phase 2 | 282 | 2016-03-22 | Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia | AZACITIDINE, LENALIDOMIDE, VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT03306264 | Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML | Phase 3 | 227 | 2024-07-01 | Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia | CEDAZURIDINE, DECITABINE | Its record names the disease | ClinicalTrials.gov |
| NCT00313586 | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | Phase 2 | 197 | 2014-11-25 | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia | AZACITIDINE, ENTINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00038675 | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | Not applicable | 125 | 2022-01-04 | Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera, Hypereosinophilic Syndrome, Mastocytosis | IMATINIB MESYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT02610777 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | Phase 2 | 120 | 2020-09-23 | Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute | AZACITIDINE, PEVONEDISTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00946647 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | Phase 1/2 | 113 | 2020-06-23 | Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia | AZACITIDINE, PANOBINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00920140 | Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias | Phase 2 | 97 | 2014-02-28 | Cancer | TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 149
See all 149 trialsComparisons in its trials37
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sabatolimab (MBG453) + Azacitidine vs Placebo + Azacitidine: deaths from any cause | 161 of 265 | 160 of 265 | 530 | NCT04266301 | Trial comparisons |
| Sabatolimab (MBG453) + Azacitidine vs Placebo + Azacitidine: serious adverse events | 174 of 263 | 164 of 265 | 528 | NCT04266301 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Number of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML | 3 of 227 | 9 of 227 | 454 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Sixty-Day Mortality Reported as Number of Participants Who Died Up to Day 60 | 15 of 220 | 14 of 223 | 443 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Thirty-Day Mortality Reported as Number of Participants Who Died Up to Day 30 | 6 of 220 | 5 of 223 | 443 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: deaths from any cause | 153 of 220 | 150 of 223 | 443 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: serious adverse events | 145 of 220 | 156 of 223 | 443 | NCT03268954 | Trial comparisons |
| Guadecitabine vs Treatment Choice: deaths from any cause | 237 of 277 | 122 of 140 | 417 | NCT02907359 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Number of Participants With CR and Marrow CR, PR and Hematologic Improvement (HI) | 112 of 206 | 117 of 208 | 414 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Number of Participants With Overall Response 2 (OR2) | 94 of 206 | 94 of 208 | 414 | NCT03268954 | Trial comparisons |
1 to 10 of 37
See all 37 comparisons in its trialsPapers from its trials68
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020311
GET https://conductscience.org/api/diseases/v1/MONDO_0020311/drugs?page=2